Datamonitor Schizophrenia KOL Interview 2
- KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.
- Abilify Maintena, Risperdal Consta, and Invega Sustenna are the main long-acting injectables (LAIs) he uses (Otsuka, JNJ), but US LAI use overall is low (5%).
- There’s nothing that differentiates Vraylar (cariprazine) from other currently available treatments (AGN/PFE).
- Patients have to be on four months of Invega Sustenna before considering switching to Trinza so its use will only be for a small set up non-compliant patients; Trinza will not take the place of Sustenna (JNJ).
- KOL feels that the partial clinical hold due to safety issues is a huge hurdle for Encenicline to overcome (FORUM).
- Acadia drug, Nuplazid (pimavanserin), is worth looking into for Parkinson’s Disease Psychosis (ACAD).
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.